Introduction
D o n e p e z i l · H C l ( E 2 0 2 0 ) , [ (R , S) -1 -b e n z y l -4 [ ( 5 , 6 -d i m e t h o x y -1-indanon)-2-yl]methyl-piperidine hydrochloride], a novel inhibitor of acetylcholinesterase, was developed for the tre a t m e n t of Alzheimer's disease (1) (2) (3) . Cholinergic deficit is one of the major pathological features of Alzheimer's disease. This deficit relates to the loss of cognition and memory, the primary symptoms of this disord e r. For its longer plasma half-life and less side e ffects, E2020 is currently used for the symptomatic treatment of A l z h e i m e r's disease in many countries. Several methods for E2020 determination, including high-perf o rmance liquid chromatography (HPLC)-UV (4-6) and HPLC with fluore s c e n c e detection (7) , have been re p o rted. However, for HPLC-UV methods, the sensitivity is rather low, and its limit of detection is only 0.5 ng/mL (6); thus, this method cannot meet the need of the p h a rmacokinetics and bioavailability studies of E2020. As for HPLC with fluorescence detection, a sophisticated column is re q u i red to separate the R and S enantiomers (7), which was not suitable for the routine analysis in clinical laboratory. This paper describes a very simple, rapid, sensitive, and specific liquid chromatography (LC)-electrospray ionization ( E S I ) -m a s s s p e c t ro m e t ry (MS) method for the determination of E2020 in the concentration range 0.1-15 ng/mL in human plasma. We used the protonated molecular ions of donepezil ([M+H] + , m / z 3 8 0 ) and internal standard (loratadine) ([M+H] + , m / z 383) as targ e t ions and determined the concentration of donepezil by computing the peak area ratio (donepezil-loratadine) of the ions and then compared them with the calibration curve. The backgro u n d components did not interf e re with the determination, and the low quantitation of the method was 0.1 ng/mL. The mean re c o v e ry of E2020 from human plasma was 99.4% ± 6.3% (ranging 93.4-102.6%). The inter-and intraday relative standard deviation (RSD) was less than 15%, which can meet the need of the pharmacokinetics and bioavailability studies of E2020.
Experimental
Reagents and materials E2020 (M w = 415, 99.8% purity) ( Figure 1A ) and its tablet (5 mg) were all obtained from Eisai Company (Suzhou, China). The internal standard (loratadine, M w = 382, 99.8% purity) 
Instrumentation and chromatographic condition
The LC system (Waters 2690 HPLC, Milford, MA) consisted of a q u a t e rn a ry pump, mobile phase vacuum degassing unit, a u t o s a m p l e r, temperature -c o n t rolled column compartment, and UV diode-array detector (DAD) 
Preparation of the stock solution
The standard stock solution was pre p a red by dissolving 10 mg E2020 in 100 mL methanol to obtain a nominal concentration of 0.1 mg/mL and then diluted with methanol to 5 µg/mL. The i n t e rnal standard stock solution was pre p a red by dissolving 15 mg loratadine in methanol to obtain a nominal concentration of 0.15 mg/mL and diluted with methanol to 1.5 µg/mL. All the stock solutions were kept at 4°C before use.
Validation procedure
The calibration curves were constructed by least-squares linear re g ression analysis of the peak area ratio of donepezil-loratadine versus the concentration of E2020. The calibration curve equation was used to calculate the concentrations of E2020 in the samples and quality control standards (QC) from their peak are a s r a t i o s .
The calibration standard samples (0.1, 0.2, 0.5, 1.0, 2.0, 5.0, 10.0, and 15.0 ng/mL) were pre p a red by spiking blank human plasma with appropriate amounts of the mentioned stock solution. QCs to determine the re c o v e ry, accuracy, and precision were independently pre p a red at low (0.2 ng/mL), medium (5.0 ng/mL), and high (15.0 ng/mL) concentrations in the same manner. The i n t e rnal standard was added to each standard and sample just prior to sample processing. All the samples were stored at -20°C b e f o re use.
Extraction procedure
Twenty microliters of the internal standard solution (1.5 µg/mL) was added into 1.0 mL of plasma (including QC
Extraction efficiency
The absolute re c o v e ry (extraction efficiency) of E2020 thro u g h the extraction pro c e d u res was determined at 0.2, 5.0, and 15.0 ng/mL (low, medium, and high concentrations) by peak are a ratio. A known amount of E2020 was added to human plasma prior to extraction as described in the Extraction pro c e d u re subsection. The internal standard was added after extraction to eliminate bias introduced by sample processing. The peak areas of E2020 (A s ) and the internal standard (A i s ) were re c o rded. The same amount of E2020 and internal standard were mixed without human plasma and extraction. The peak area of E2020 (A' s ) and the internal standard (A' i s ) were also re c o rded. The re c o v e ry was obtained by the equation:
Pharmacokinetic studies in healthy, young, Chinese subjects Twenty healthy, young, male volunteers age 19 to 23 years and weighing from 55 to 70 kg gave their written consent to part i c ipate in the study. They were each judged healthy on the basis of their medical history and the results of a physical examination, 
Pharmacokinetic data analysis and statistics
The pharmacokinetic parameters of E2020 were calculated by using 3P97 program (the Chinese Society of Mathematical P h a rmacology), and a two-compartmental open linear pharm acokinetic model was fitted to the plasma concentration data. Values for area under the curve (AUC), oral clearance (Cl/F), the plasma elimination half-life of the β-phase (T1/2), and mean re s idence time (MRT) were calculated by the following equations:
Eq. 2
Cl/F = Dose/AUC 0'∞ Eq. 4 T1 ⁄ 2 = 0.693/λ n Eq. 5
Eq. 6
w h e re λ n = elimination rate constant of terminal phase. Data w e re expressed as mean ± SD of sample.
Results and Discussion
Separation and specificity The typical chromatograms and mass spectrum from the study of E2020 in human plasma are shown in Figures 2 and 3 . Shown in Figure 2 are the chromatograms for donepezil and loratadine f rom a sample of a volunteer 4 h after the oral administration of 5 mg E2020. The retention times of donepezil and loratadine were a p p roximately 4 and 12 min, re s p e c t i v e l y. For both the drug and i n t e rnal standard, the chromatograms were free of interf e r i n g peaks at their respective retention times. In mass spectra (Figure  3) , the major ion was the protonated molecular ions as the base peaks (m / z 380), and only a few unidentified fragment ions were Linearity, accuracy, and precision Calibration curves were plotted as the peak area ratio ( d ru g -i n t e rnal standard) versus drug concentration. Results for the calibration curve (n = 9) showed good linearity (r = 0.9998) over the concentration range 0.1-15 ng/mL with an equation of:
Eq. 7
w h e re c = donepezil concentration in ng/mL and f = donepezil a rea/loratadine area. The limit of quantitation (LOQ) was 0.1 ng/mL, with a precision (RSD) less than 15%. Accuracy and precision were determined by calculating the intra-and interassay variabilities at three concentrations (0.2, 5.0, and 15.0 ng/mL) for five replicates. The results are shown in Ta b l e I. These results indicate that the method was reliable within the analytical ranges, and the use of the internal standard was very e ffective for re p roducibility by LC-MS.
Recovery
The mean re c o v e ry of E2020 from human plasma was 99.4% ± 6.3% (ranging 93.4-102.6%). This data is the average of the thre e QC standards shown in Table II . The stability of E2020 in plasma was ascertained through two freeze-thaw cycles of QC samples. The results indicate that E2020 is very stable in plasma.
Application to healthy Chinese subjects
F i g u re 4 shows a profile of mean plasma concentrations (n = 20) for E2020 versus time. The main pharmacokinetic parameters of E2020 in 20 volunteers after a single oral dose (5 mg) of E2020 are listed in Table III . These results were somewhat diff e rent from what was obtained in previous studies (4) . Things leading to the diff e rence deserve thorough investigation.
Conclusion
In conclusion, the use of LC-MS provides an accurate, pre c i s e , and reliable method for the measurement of E2020 concentrations in human plasma for up to 192 h after the oral administration of 5 mg E2020 in healthy volunteers. The assay proved to be fast, simple, sensitive, and specific because of the inherent selectivity of MS.
